Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Shares Outstanding (Diluted Average) (2021 - 2025)

Precision Biosciences (DTIL) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $12.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 86.32% to $12.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Dec 2025, up 86.32% year-over-year, with the annual reading at $12.8 million for FY2025, 86.32% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $12.8 million at Precision Biosciences, up from $10.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $80.1 million in Q3 2022, with the low at $2.9 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $23.5 million, with a median of $6.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) crashed 95.21% in 2023, then soared 86.32% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $58.7 million in 2021, then crashed by 95.01% to $2.9 million in 2022, then skyrocketed by 31.11% to $3.8 million in 2023, then soared by 79.2% to $6.9 million in 2024, then skyrocketed by 86.32% to $12.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $12.8 million, $10.7 million, and $11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.